Dr Matthias joins Noxxon Pharma
pharmafile | February 9, 2011 | Appointment | Research and Development | Dr Matthias Baumann, Noxxon Pharma, appointment, research and development
Berlin-based biotech Noxxon Pharma has appointed Dr Matthias Baumann as chief medical officers.
He joins from Focus Clinical Drug Development, where he spent eight years as chief scientific officer and managing director, and prior to this he held a number pre-clinical and clinical development roles with Hoffmann La Roche and Boehringer Mannheim.
Iain Buchanan, Noxxon’s chief executive, said: “I am pleased to welcome Matthias to the management team at Noxxon. He brings valuable development experience to the company at a time when we will look to advance multiple pipeline projects through clinical proof of concept in the coming 24 months.”
Noxxon is developing a new class of therapeutics called Spiegelmers, oligonucleotides made from the L-stereoisomer of RNA that can be engineered to bind specifically to a precisely defined biological target and have been shown to be potent inhibitors.
Clinical and pre-clinical studies have so far shown them to be safe, well-tolerated, biologically stable and non-immunogenic.
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …






